Agents and Actions

, Volume 38, Issue 1–2, pp 281–285 | Cite as

Enhancingin vivo effect of propranolol on human lymphocyte function is not due to stereospecific beta-adrenergic blockade

  • H. Mangge
  • B. Pietsch
  • W. Lindner
  • H. Warnkross
  • G. Leb
  • K. Schauenstein
Molecular Immunopathology


Immunoenhancingin vivo effects of beta-adrenergic blockers have been previously ascribed to a reduced beta-receptor-mediated immunosuppression. In the present study using a whole blood stimulation assay, the effects of a five-day treatment with the purified (R)- or (S)-isomer of propranolol (3×40 mg/day) on the polyclonalin vitro responsiveness of peripheral blood lymphocytes (PBL) of normothyroid and hyperthyroid persons were assessed. It is shown that both isomers likewise exhibit a significant enhancing effect on the proliferative response of PBL to T and B cell mitogens, which strongly argues for nonspecific effects of propranolol to be responsible rather than a specific beta-adrenergic receptor blockade.


Propranolol Blood Lymphocyte Peripheral Blood Lymphocyte Proliferative Response Human Lymphocyte 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    D. L. Felten, S. Y. Felten, D. L. Bellinger, S. L. Carlson, K. D. Ackerman, K. S. Meaden and J. A. Olschowsky,Nor adrenergic sympathetic neural interactions with the immune system: Structure and function. Immunol. Rev.100, 225–260 (1987).Google Scholar
  2. [2]
    J. W. Hadden, E. M. Hadden and E. Middleton,Lymphocyte blast transformation. Demonstration of adrenergic receptors in human peripheral lymphocytes. Cell. Immunol.1, 583–595 (1970).Google Scholar
  3. [3]
    L. T. Williams, R. Snyderman and R. J. Lefkowitz,Identification of beta adrenergic receptors in human lymphocytes by (−) 3 H-alprenolol binding. J. Clin. Invest.57, 149–155 (1976).Google Scholar
  4. [4]
    D. L. Johnson and M. A. Gordon,Characteristics of adrenergic binding sites associated with murine lymphocytes isolated from spleen. J. Immunopharmacol.2, 435–452 (1980).Google Scholar
  5. [5]
    R. D. Aarons and P. B. Molinoff,Changes in the density of beta adrenergic receptors in rat lymphocytes, heart, and lung after chronic treatment with propranolol. J. Pharmacol. Exp. Ther.221, 439–443 (1982).Google Scholar
  6. [6]
    M. M. Khan, P. Sansoni, E. D. Silverman, E. G. Engleman and K. L. Melmon,Beta-adrenergic receptors on human suppressor, helper and cytolytic lymphocytes. Biochem. Pharmacol.7, 1137–1142 (1986).Google Scholar
  7. [7]
    H. O. Besedovsky, A. DelRey, E. Sorkin, M. DePrada and H. H. Keller,Immunoregulation by sympathetic nervous system. Trends Pharmacol. Sci.2, 236–238 (1981).Google Scholar
  8. [8]
    S. Livnat, K. S. Madden, D. L. Felten and S. Y. Felten,Regulation of the immune system by sympathetic neural mechanisms. Prog. Neuropsychopharmacol. Biol. Psychiatry11, 145–152 (1987).Google Scholar
  9. [9]
    S. Titinchi and B. Clark,Alpha 2-adrenoceptors in human lymphocytes: Direct characterization by (3H)yohimbine binding. Biochem. Biophys. Res. Commun.121, 1–7 (1984).Google Scholar
  10. [10]
    N. H. Bisphoric, H. J. Cohen and R. J. Lefkowitz,Beta-adrenergic receptors in lymphocyte subpopulations. J. Allergy Clin. Immunol.65, 29–33 (1980).Google Scholar
  11. [11]
    P. Felsner, D. Hofer, I. Rinner, H. Mangge, M. Gruber, W. Korsatko and K. Schauenstein,Continuous in vivo treatment with catecholamines suppresses in vitro reactivity of peripheral blood T lymphocytes via alpha-mediated mechanisms. J. Neuroimmunol.37, 47–57 (1992).Google Scholar
  12. [12]
    H. R. Bourne, L. M. Lichtenstein, K. L. Melmon, C. S. Henney, Y. Weinstein and G. M. Shearer,Modulation of inflammation and immunity by c-AMP: Receptors for vasoactive hormones and mediators for inflammation regulate many leucocyte functions. Science184, 19–28 (1974).Google Scholar
  13. [13]
    G. M. Kammer,The adenylate cyclase-cAMP-protein kinase. A pathway and regulation of the immune response. Immunol. Today9, 222–229 (1988).Google Scholar
  14. [14]
    T. L. Krasnikova, M. V. Kozlova, V. U. Kalentchuk and Y. Suvorov,Beta-blocker action on lymphocyte proliferative response in essential hypertension. Cor Vasa30, 110–114 (1988).Google Scholar
  15. [15]
    A. S. Maisel, D. Murray, M. Lotz, A. Rearden, M. Irwin and M. C. Michel,Propranolol treatment affects parameters of human immunity. Immunopharmacology22, 157–164 (1991).Google Scholar
  16. [16]
    H. Mangge, F. Beaufort, M. Neubauer, M. Samitz and K. Schauenstein,Peripheral blood lymphocytes of non-leukemic lymphoma patients exhibit aberrant expression of T-cell activation markers after polyclonal stimulation in vitro. Cancer66, 677–683 (1990).Google Scholar
  17. [17]
    S. A. Doggrell,The membrane stabilizing and beta 1-adrenoceptor blocking activity of (+) and (−) propranolol on the rat left atria. Gen. Pharmacol.21, 677–680 (1990).Google Scholar
  18. [18]
    B. Hallengren, A. Forsgren and A. Melander,Influence of beta-adrenoceptor blocking agents on lymphocyte functions in vitro. Br. J. Pharmacol.13, 543–546 (1986).Google Scholar
  19. [19]
    K. Stoschitzky, W. Lindner, M. Rath, C. Leitner, G. Uray, G. Zernig, T. Moshammer and W. Klein,Stereoselective hemodynamic effects of (R)- and (S)-propranolol in man. Naunyn-Schmiedeberg's Arch. Pharmacol.339, 474–478 (1989).Google Scholar
  20. [20]
    M. Heilig, M. Irwin, I. Grewal and E. Sercarz,Sympathetic regulation of T-helper cell function: Mediation by changes in antigen processing/presentation. Abstract. Hans Selye Symposia in Neuroendocrinology, August 17–21, 1992, Budapest, Hungary.Google Scholar
  21. [21]
    R. J. Cody, L. H. Calabrese, J. D. Clough, R. C. Tarazi and E. L. Bravo,Development of antinuclear antibodies during acebutolol therapy. Clin. Pharmacol. Ther.25, 801–805 (1979)Google Scholar
  22. [22]
    R. J. Booth, Y. Jocelyn, S. Bullock and J. D. Wilson,Antinuclear antibodies in patients on acebutolol, Brit. J. Clin. Pharmacol.9, 515–517 (1980).Google Scholar
  23. [23]
    J. D. Wilson,Antinuclear antibodies and cardiovascular drugs. Drugs19, 292–305 (1980).Google Scholar
  24. [24]
    E. B. Raftery and A. M. Denman,Systemic lupus erythematosus syndrome induced by practolol. Brit. Med. J.2, 452–455 (1973).Google Scholar
  25. [25]
    M. C. Heng and M. K. Heng,Beta-adrenoceptor antagonist-induced psoriasiform eruption. Clinical and pathogenetic aspects. Int. J. Dermatol.27, 619–627 (1988).Google Scholar

Copyright information

© Birkhäuser Verlag 1993

Authors and Affiliations

  • H. Mangge
    • 1
  • B. Pietsch
    • 2
  • W. Lindner
    • 3
  • H. Warnkross
    • 2
  • G. Leb
    • 2
  • K. Schauenstein
    • 4
  1. 1.Department of PediatricsUniversity of Graz School of MedicineGrazAustria
  2. 2.Department of Internal MedicineUniversity of Graz School of MedicineGrazAustria
  3. 3.Department of Pharmaceutical ChemistryUniversity of Graz School of MedicineGrazAustria
  4. 4.Department of General and Experimental PathologyUniversity of Graz School of MedicineGrazAustria

Personalised recommendations